Trial Profile
A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pimurutamab (Primary) ; Dexamethasone; Diphenhydramine; Ondansetron; Paracetamol
- Indications Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Shanghai Henlius Biotech
- 13 Mar 2021 Results published in the Investigational New Drugs
- 28 Jul 2019 Status changed from recruiting to completed.
- 11 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.